Literature DB >> 21256566

Laparoscopic radiofrequency ablation of renal tumors: 32-month mean follow-up results of 106 patients.

Changwei Ji1, Xiaogong Li, Shiwei Zhang, Weidong Gan, Gutian Zhang, Lingqi Zeng, Xiang Yan, Tieshi Liu, Huibo Lian, Hongqian Guo.   

Abstract

OBJECTIVE: To report our experience of laparoscopic radiofrequency ablation (RFA) on patients with renal tumors. RFA has been increasingly applied in the management of small renal tumors. However, it was performed mostly via percutaneous approach, with limited cases and a short follow-up period.
METHODS: From February 2006 to March 2008, laparoscopic RFA was performed on 106 renal tumors (size range: 0.9-5.5 cm) in 106 selected patients (74 men and 32 women, age range: 25-81 years). Initial contrast-enhanced computed tomography (CT) examination was performed seven days after the procedure, with subsequent CT assessment at three months, six months, and every six months thereafter. Serum creatinine measurement was conducted along with each time CT examination.
RESULTS: The mean follow-up period was 32 months (range: 12-48). All 106 tumors were biopsied before RFA, of which 90 were diagnosed as renal cell carcinoma (RCC) (84.90%). There was one incomplete ablation. One case with radiographic local recurrence was then proved by pathologic analysis of the nephrectomy specimen to have no cancer cells. The local tumor control rate was 98.1% (104/106). Of the 90 RCC cases, the disease-free survival rate was 97.8% (88/90); both the cancer-specific and the overall survival rate were 100%. No death or renal failure after the procedure has yet been found.
CONCLUSIONS: Our results showed that the laparoscopic RFA on small renal mass was safe, with outcomes of patients comparable with those by partial nephrectomy and percutaneous RFA. Further research and a longer follow-up period are needed to confirm our results.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21256566     DOI: 10.1016/j.urology.2010.10.014

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

Review 1.  Update on thermal ablation of renal cell carcinoma: oncologic control, technique comparison, renal function preservation, and new modalities.

Authors:  Ronald J Zagoria; David D Childs
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  Preoperative patient counseling for diagnostic renal biopsy and complications with renal radiofrequency ablation.

Authors:  Scott M Castle; Michael A Gorin; Vladislav Gorbatiy; Raymond J Leveillee
Journal:  World J Urol       Date:  2012-01-15       Impact factor: 4.226

3.  [Organ-preserving renal tumor surgery for renal cell carcinoma ≥T1b: operative technique, complications and oncological control].

Authors:  C Piper; D Pfister; D Porres; A Mahnken; B Brehmer; A Heidenreich
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

4.  Urologic and interventional radiology treatment of renal cell carcinomas-similarities and differences.

Authors:  Diep Nguyen; Eric vanSonnenberg; Paul Kang; Peter R Mueller
Journal:  Ann Transl Med       Date:  2019-07

5.  VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1α.

Authors:  Feng-qiang Yang; Min Liu; Feng-ping Yang; Jianping Che; Wei Li; Wei Zhai; Guang-chun Wang; Jun-hua Zheng; Xi Li
Journal:  Mol Biol Rep       Date:  2014-01-05       Impact factor: 2.316

Review 6.  Thermal Ablation of Renal Tumors: Indications, Techniques and Results.

Authors:  Marc Regier; Felix Chun
Journal:  Dtsch Arztebl Int       Date:  2015-06-12       Impact factor: 5.594

Review 7.  Ablative therapies for small renal tumours.

Authors:  Arturo Castro; Lawrence C Jenkins; Nelson Salas; Gideon Lorber; Raymond J Leveillee
Journal:  Nat Rev Urol       Date:  2013-04-23       Impact factor: 14.432

8.  Perioperative outcomes of zero ischemia radiofrequency ablation-assisted tumor enucleation for renal cell carcinoma: results of 182 patients.

Authors:  Chengwei Zhang; Xiaozhi Zhao; Suhan Guo; Changwei Ji; Wei Wang; Hongqian Guo
Journal:  BMC Urol       Date:  2018-05-15       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.